RGRX — RegeneRx Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $1.33m
- $0.08m
Annual income statement for RegeneRx Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.07 | 0.077 | 0.077 | 0.077 | 0.077 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.39 | 1.34 | 1.37 | 1.35 | 1.48 |
| Operating Profit | -1.32 | -1.26 | -1.29 | -1.27 | -1.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.99 | -1.4 | -1.52 | -1.6 | -1.73 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.99 | -1.4 | -1.52 | -1.6 | -1.73 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.99 | -1.4 | -1.52 | -1.6 | -1.73 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.99 | -1.49 | -1.52 | -1.6 | -1.73 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.65 | -1.14 | -1.14 | -1.19 | -1.2 |